Singapore markets open in 41 minutes

Clene Inc. (CLNN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3826-0.0137 (-3.46%)
At close: 04:00PM EDT
0.3731 -0.01 (-2.48%)
After hours: 07:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.3963
Open0.4000
Bid0.3705 x 100
Ask0.3797 x 100
Day's range0.3705 - 0.4000
52-week range0.2500 - 0.9500
Volume320,963
Avg. volume889,422
Market cap49.139M
Beta (5Y monthly)0.44
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference

    SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at H.C. Wainwright’s 5th Annual Neuro Perspectives Vi

  • GlobeNewswire

    Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

    CNM-Au8 demonstrated neuroprotective effects in an in vitro model of Rett Syndrome, a rare pediatric neurodevelopmental diseaseCNM-Au8 also demonstrated rescue of mitochondrial deficits in induced astrocytes derived from Rett patientsInvited oral presentation and poster presented on June 19, 2024, at the International Rett Syndrome Foundation 2024 Annual Meeting in Westminster, Colorado SALT LAKE CITY, June 21, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Cle

  • GlobeNewswire

    Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

    Survival analyses with CNM-Au8 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baseline (hazard ratio: 0.431, p=0.0002)Average of 28% NfL reduction observed in an NfL responder subset (geometric mean ratio, change at Week 76 post-baseline: 0.72, p<0.0001) More than 650 patient years of CNM-Au8 treatment exposure without any identified safety signals SALT LAKE CITY, June 18, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its